sucrose and Hyperphosphatemia

sucrose has been researched along with Hyperphosphatemia in 36 studies

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's24 (66.67)24.3611
2020's12 (33.33)2.80

Authors

AuthorsStudies
Ketteler, M; Sprague, SM1
Araujo, R; Bancu, I; Bonal, J; Graterol, F; Merino-Ribas, A; Noguera-Julian, M; Paredes, R; Sampaio-Maia, B; Vergara, A1
Coyne, DW; Kalantar-Zadeh, K; Ramos, R; Sprague, SM; Vervloet, M1
Andrews, ES; Kendrick, J; Perez, L; Ramirez-Renteria, L; Reddin, R; Teitelbaum, I; Wilson, G; You, Z1
Faitatzidou, D; Lioulios, G; Minasidis, I; Papagianni, A; Sampani, E; Sarafidis, PA; Stangou, M; Tsouchnikas, I; Vainas, A1
Hirai, K; Hoshino, T; Ito, K; Kitano, T; Minato, S; Miyazawa, H; Morishita, Y; Ookawara, S; Shindo, M; Ueda, Y1
Covic, AC; Floege, J; Ketteler, M; Perrin, A; Rastogi, A; Sprague, SM; Walpen, S1
Abitbol, CL; Ahn, SY; Balgradean, M; Enoiu, M; Fathallah-Shaykh, S; Fila, M; Greenbaum, LA; Jankauskiene, A; Jeck, N; Klaus, G; Nelson, R; Paredes, A; Perrin, A; Stoica, C; Swinford, RD; Wickman, L1
Arens, HJ; Chazot, C; Di Benedetto, A; Ferreira, A; Feuersenger, A; Gurevich, K; Ramos, R; Stuard, S; Walpen, S; Wolf, M1
Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y1
Li, W; Liao, X; Ou, J; Rao, J; Xue, C; Zhu, Y1
Fujino, T; Kaburagi, N; Morimoto, K; Oya, M; Takemitsu, TY; Yamashita, N; Yoshida, T1
Covic, AC; Floege, J; Ketteler, M; Lisk, LJ; Mann, J; Rakov, V; Rastogi, A; Spinowitz, B; Sprague, SM1
Akizawa, T; Fukagawa, M; Koiwa, F; Yokoyama, K1
Bataille, P; Daroux, M; Delattre, V1
Anderson, L; Coyne, DW; Ficociello, LH; Kossmann, RJ; Maddux, FW; Mullon, C; Ofsthun, NJ; Parameswaran, V; Sprague, SM; Vemula, S1
Hayashi, H; Ichie, T; Sugiura, Y; Sugiyama, T; Suzuki, D1
Anderson, L; Coyne, DW; Ficociello, LH; Kalantar-Zadeh, K; Kossmann, RJ; Kwoh, C; Mullon, C; Ofsthun, NJ; Parameswaran, V1
Fujii, H; Hamano, T; Isaka, Y; Teramukai, S; Tsujimoto, Y1
Covic, AC; Floege, J; Ketteler, M; Rakov, V; Rastogi, A; Spinowitz, B; Sprague, SM; Walpen, S1
Floege, J; Sprague, SM1
Alfieri, C; Cozzolino, M; Gallieni, M; Malberti, F; Mazzaferro, S; Messa, P; Russo, D1
Chazot, C; Fadel, B; Jean, G; Kareche, M; Puyoo, O1
Davis, S; Ficociello, LH; Kalantar-Zadeh, K; Kendrick, J; Kossmann, RJ; Mullon, C; Ofsthun, NJ; Parameswaran, V1
Al-Makki, A; Bousher, A; Shepler, B; Sutton, J1
Cozzolino, M; Funk, F; Phan, O; Rakov, V; Teitelbaum, I1
Chong, EM; Covic, AC; Floege, J; Gaillard, S; Ketteler, M; Lisk, LJ; Mann, JF; Rastogi, A; Spinowitz, B; Sprague, SM1
Greig, SL; Plosker, GL1
Lederer, SR; Schmid, H1
Ademi, Z; Blank, PR; Braunhofer, PG; Gutzwiller, FS; Pfeil, AM; Schwenkglenks, M; Szucs, TD1
Jang, SM; Pai, AB; Wegrzyn, N1
Kobayashi, M; Maruyama, I; Maruyama, K; Tatemichi, S; Yaguchi, A; Yonekubo, S1
Floege, J1
Covic, AC; Floege, J; Ketteler, M; Lisk, L; Rakov, V; Rastogi, A; Sprague, SM1
Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM1
Akizawa, T; Fukagawa, M; Koiwa, F; Terao, A; Yokoyama, K1

Reviews

11 review(s) available for sucrose and Hyperphosphatemia

ArticleYear
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Expert opinion on drug safety, 2021, Volume: 20, Issue:12

    Topics: Chelating Agents; Drug Combinations; Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose

2021
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Journal of nephrology, 2022, Volume: 35, Issue:3

    Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Phosphorus; Prospective Studies; Randomized Controlled Trials as Topic; Renal Dialysis; Retrospective Studies; Sucrose

2022
Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
    International urology and nephrology, 2021, Volume: 53, Issue:9

    Topics: Anemia; Carbonates; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Magnesium; Randomized Controlled Trials as Topic; Renal Dialysis; Starch; Sucrose; Treatment Outcome

2021
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:10

    Topics: Chelating Agents; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Government Regulation; Humans; Hyperphosphatemia; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; Treatment Outcome

2018
[Hyperphosphatemia in dialysis: which binder?]
    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:5

    Topics: Chelating Agents; Chelation Therapy; Cohort Studies; Drug Combinations; Ferric Compounds; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Multicenter Studies as Topic; Patient Compliance; Phosphates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Sucrose

2018
A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Clinical therapeutics, 2014, Dec-01, Volume: 36, Issue:12

    Topics: Chelating Agents; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; United States

2014
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Current drug metabolism, 2014, Volume: 15, Issue:10

    Topics: Animals; Chelating Agents; Disease Models, Animal; Dogs; Drug Combinations; Ferric Compounds; Gastrointestinal Absorption; Humans; Hyperphosphatemia; Kidney; Phosphates; Rats; Renal Insufficiency, Chronic; Risk Assessment; Sucrose; Uremia; Vascular Calcification

2014
Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Drugs, 2015, Volume: 75, Issue:5

    Topics: Chelating Agents; Drug Combinations; Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Phosphates; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose

2015
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14

    Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose

2015
Iron-based phosphate binders--a new element in management of hyperphosphatemia.
    Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:1

    Topics: Animals; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Medication Adherence; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Sucrose

2016
Phosphate binders in chronic kidney disease: a systematic review of recent data.
    Journal of nephrology, 2016, Volume: 29, Issue:3

    Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Sucrose

2016

Trials

12 trial(s) available for sucrose and Hyperphosphatemia

ArticleYear
Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.
    International urology and nephrology, 2022, Volume: 54, Issue:8

    Topics: Acetates; Calcium Compounds; Drug Combinations; Ferric Compounds; Gastrointestinal Microbiome; Humans; Hyperphosphatemia; Pilot Projects; Renal Dialysis; RNA, Ribosomal, 16S; Sucrose

2022
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Nephron, 2020, Volume: 144, Issue:9

    Topics: Adult; Age Factors; Aged; Calcimimetic Agents; Chelating Agents; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose; Vitamin D

2020
Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
    Pediatric nephrology (Berlin, Germany), 2021, Volume: 36, Issue:5

    Topics: Adolescent; Child; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose

2021
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
    Journal of the American Society of Nephrology : JASN, 2021, Volume: 32, Issue:3

    Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult

2021
One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, Nov-01, Volume: 32, Issue:11

    Topics: Adult; Aged; Combined Modality Therapy; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Medication Adherence; Middle Aged; Peritoneal Dialysis; Phosphates; Sucrose; Treatment Outcome

2017
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2017, Volume: 27, Issue:5

    Topics: Aged; Asian People; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sucrose; Treatment Outcome

2017
Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
    Clinical and experimental nephrology, 2018, Volume: 22, Issue:4

    Topics: Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Sucrose

2018
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 07-01, Volume: 34, Issue:7

    Topics: Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sevelamer; Sucrose; Time Factors; Treatment Outcome

2019
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:6

    Topics: Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Male; Middle Aged; Phosphorus; Prognosis; Renal Dialysis; Sucrose; Time Factors

2015
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, Aug-01, Volume: 32, Issue:8

    Topics: Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Male; Middle Aged; Prognosis; Renal Dialysis; Sucrose

2017
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    American journal of nephrology, 2016, Volume: 44, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Biomarkers, Pharmacological; Bone Density Conservation Agents; Chelating Agents; Drug Combinations; Drug Interactions; Ergocalciferols; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose

2016
Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
    Nephrology (Carlton, Vic.), 2017, Volume: 22, Issue:4

    Topics: Administration, Oral; Aged; Biomarkers; Calcium; Chelating Agents; Drug Administration Schedule; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose; Tablets; Time Factors; Treatment Outcome

2017

Other Studies

13 other study(ies) available for sucrose and Hyperphosphatemia

ArticleYear
A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
    BMC nephrology, 2022, 07-09, Volume: 23, Issue:1

    Topics: Adult; Aged; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Hypoalbuminemia; Middle Aged; Nutritional Status; Peritoneal Dialysis; Phosphates; Phosphorus; Pilot Projects; Prospective Studies; Serum Albumin; Sucrose

2022
Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
    Blood purification, 2020, Volume: 49, Issue:4

    Topics: Aged; Aged, 80 and over; Anemia; Biomarkers; Drug Combinations; Female; Ferric Compounds; Ferritins; Humans; Hyperphosphatemia; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sucrose

2020
Eosinophilic peritonitis induced by sucroferric oxyhydroxide.
    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 2020, Volume: 40, Issue:4

    Topics: Drug Combinations; Eosinophilia; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Sucrose

2020
The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    BMC nephrology, 2020, 12-07, Volume: 21, Issue:1

    Topics: Aged; Chelating Agents; Databases, Factual; Drug Combinations; Europe; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sucrose

2020
Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
    International urology and nephrology, 2022, Volume: 54, Issue:4

    Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Renal Dialysis; Retrospective Studies; Sucrose

2022
[Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?]
    Nephrologie & therapeutique, 2017, Volume: 13 Suppl 1

    Topics: Chelating Agents; Drug Combinations; Evidence-Based Medicine; Ferric Compounds; Guidelines as Topic; Humans; Hyperphosphatemia; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Sucrose; Treatment Outcome

2017
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
    Clinical nephrology, 2017, Volume: 88, Issue:8

    Topics: Adult; Aged; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Sucrose

2017
Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Die Pharmazie, 2017, Feb-01, Volume: 72, Issue:2

    Topics: Aged; Chelating Agents; Constipation; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Male; Middle Aged; Phosphorus; Renal Dialysis; Sucrose; Time Factors

2017
Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
    American journal of nephrology, 2018, Volume: 47, Issue:3

    Topics: Adult; Aged; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Phosphorus; Retrospective Studies; Sucrose

2018
[Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France].
    Nephrologie & therapeutique, 2019, Volume: 15, Issue:1

    Topics: Aged; Cohort Studies; Drug Combinations; Female; Ferric Compounds; Ferritins; France; Humans; Hyperphosphatemia; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Sucrose

2019
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2019, Volume: 29, Issue:5

    Topics: Adult; Aged; Chelating Agents; Cohort Studies; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Medication Adherence; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Renal Dialysis; Renal Insufficiency; Sucrose; Time Factors; Treatment Outcome

2019
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    PharmacoEconomics, 2015, Volume: 33, Issue:12

    Topics: Cost-Benefit Analysis; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Markov Chains; Models, Economic; National Health Programs; Quality-Adjusted Life Years; Renal Dialysis; Scotland; Sevelamer; Sucrose

2015
Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
    Drug research, 2016, Volume: 66, Issue:5

    Topics: Administration, Oral; Animals; Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Hyperphosphatemia; Lanthanum; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sevelamer; Sucrose

2016